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BACKGROUND Data published in the study Simplicity III reported
that the effectiveness of the procedure is directly related to the
number of ablative points with a threshold calculated as about 14
points. In our experience this threshold has been exceeded since we
use the device Enlightn St Jude whose conformation allows both a
more favorable contact of the electrodes with the vessel wall and the
possibility of varying those points more precisely. This result can be
achieved only beginning the ablation as distally as possible in the
renal arteries, performing the procedure even in the branches when
they have a minimum diameter of 4 mm. The purpose of our study
was to see if a larger number of points of ablation were related to a
greater effectiveness of the procedure.
METHODS In our center 29 patients (17 men. Average age 58.4  14
years) with resistant hypertension were submitted to transcatheter
renal denervation between November 2011 and May 2015. 12 patients
had signs of hypertensive vascular damage. All of them were taking an
average of 4 antihypertensive drugs in dosage ceiling, including a
diuretic. The values of mean arterial pressure were: 176/98  17/
14 mmHg. For all patients we used the femoral arterial access. All pa-
tients were treated with dual anti platelet therapy for 3/6 months after
the procedure. 7 patients had complex renal anatomy: 2 patients had
superior polar arteries, 1 patient presented one superior and one infe-
rior polar artery and 4 patients presented an early bifurcation (length of
the proximal segment <10 mm), all arteries had a diameter >4 mm. 16
patients, treated from March 2014 to May 2015, were treated with an
average of 24-36 ablative points overall comparedwith theﬁrst group of
patients in which the ablative points were only 16.
RESULTS All patients were treated successfully. Renal function
remained stable. The average pressure was reduced by about
15 mmHg at six months in the group of patients treated with 16
ablative points, whereas in patients treated with 24-36 ablative points
this reduction was approximately 27 mmHg. One patient of the ﬁrst
group was hospitalized for hypertensive crisis seven months after the
procedure, the values of blood pressure normalized after about one
year and are still stable. All patients have gradually reduced the
number of antihypertensive drugs (1-2 against 4 or more pre-proce-
dure). Computed tomography angiography of the patients with com-
plex renal vascular anatomy (6) and of the patients in which the
ablation was performed very distally and showed a more important
parietal notch of the renal artery after the procedure (16) documented
the absence of parietal complications three months after the
procedure.
CONCLUSIONS Our experience conﬁrms that renal denervation is an
effective procedure in the treatment of hypertensive patients re-
fractory to medical therapy. A larger number of ablative points seems
to be strongly related to an increased efﬁcacy of treatment.
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BACKGROUND Percutaneous renal artery denervation has been
shown to decrease blood pressure among patients with resistant
arterial hypertension. We present in this review a meta-analysis of
all randomized controlled trials evaluating effectiveness andcomplications of catheter-based RDN for blood pressure control in
patients with resistant hypertension.
METHODS We searched Pub Med, Cochrane and Scopus were systemati-
cally searched up for all RTCs up to June 2015. Primary outcomes were 6
months reduction of ofﬁce systolic and diastolic blood pressure. Secondary
outcomes were 24 hours systolic blood pressure reduction and more than
10mmHgsystolic bloodpressure reduction.Weusedﬁxedor randomEffect
analysis using the Cochrane Handbook of Systematic Reviews.
RESULTS Out of 860 articles, ﬁve RCTs were included. The pooled
data provided a total of 776 patients, being 476 in the RDN group and
300 patients in the control group with mean 6 months of follow-up.
Both groups had ofﬁce systolic and diastolic blood pressures signiﬁ-
cantly decreased (p<0.05). There was no signiﬁcant difference in SBP
reduction between the two groups but RDN had higher DBP reduction
(p<0.05). RDN group presented with a trend towards higher decrease
of 24-hours systolic blood pressure (mean reduction -5.22; p¼0.07).
RDN trended to present more patients who had  10 mmHg SBP
decrease (p ¼0.1) (Figure 1).CONCLUSIONS Resistant hypertension treated with catheter-based
RDN respond well to blood pressure reduction and with sustained
control. It is yet to be determined if some RDN catheters are capable to
provide more concise results and therefore lead to better procedural
outcomes. Therefore more randomized clinical data are warranted.
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BACKGROUND Percutaneous sympathetic renal artery denervation is
available for the treatment of patients with resistant hypertension and
preserved renal function. We investigated the safety and efﬁcacy of a
